Research Use Only (RUO). This article is for education and shares what published science says about a research compound. It is not medical advice, and nothing here is a suggestion to use any peptide on people or animals.
Is retatrutide FDA approved? Short answer: no, not as of 2026. Here is the current, factual status - who makes it, where it is in testing, and when it might arrive. This is regulatory information, not advice.
Current FDA status
Retatrutide is not FDA approved. Drugs.com states plainly that it 'is not yet FDA approved and is still working its way through Phase 3 clinical trials.' It is an investigational compound, which means it is being studied but has not cleared full regulatory review.
Who makes retatrutide?
Eli Lilly and Company developed retatrutide. Its research code is LY3437943. Lilly is running the Phase 3 program known as TRIUMPH.
Where it stands in trials
Retatrutide has completed Phase 2 and reported positive Phase 3 TRIUMPH results, including large weight reductions in the trials. Lilly has said several more Phase 3 trials in obesity and type 2 diabetes are expected to complete in 2026.
When might retatrutide be available?
After the trials finish, Lilly would need to submit a New Drug Application (NDA) to the FDA, and that review typically takes around 10-12 months. Based on that path, industry coverage suggests a possible approval window around 2027-2028 if everything proceeds. Timelines can change.
Retatrutide research materials at Dissolv Labs
Dissolv Labs supplies high-purity compounds as reference materials for laboratory research only. They are not for human or animal use.
Frequently asked questions
Is retatrutide legal to buy?
It is sold as a Research Use Only reference compound, not as an approved medicine. It is not available by prescription.
When will retatrutide be available?
Possibly around 2027-2028 if trials and FDA review proceed, but no date is confirmed.
Who owns retatrutide?
Eli Lilly and Company develops it under the code LY3437943.
The bottom line
As of 2026, retatrutide is not FDA approved. It is an Eli Lilly investigational peptide in Phase 3, with a possible approval window later this decade. Today it exists only as a research compound.
Sources
- Drugs.com: Retatrutide history and FDA approval status
- Eli Lilly: Retatrutide Phase 3 (TRIUMPH) topline results
- AJMC: Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1
Disclaimer: All Dissolv Labs products are sold for Research Use Only and are not for human or veterinary use. This content is educational and is not medical advice, diagnosis, treatment guidance, or a recommendation to consume any substance.
